RevenanasBook a free audit

Funding

T-Therapeutics raises $133M Series B for bispecific TCR pipeline

Biotech

Funding

Key Facts

Signal Type

Funding

Industry

Biotech

Companies

T-Therapeutics, Eli Lilly, Johnson & Johnson, Sanofi, Merck KGaA

Date

What Happened

T-Therapeutics, a Cambridge, England-based biotech, raised a $133M Series B to advance its TCR-CD3 bispecific pipeline. The round was co-led by Advent Life Sciences and British Business Bank, with participation from Eli Lilly, Johnson & Johnson Innovation, Merck KGaA, Sanofi, Samsara BioCapital, Sofinnova Partners, and F-Prime.

The company is progressing TTX-008, an oncology TCR-CD3 bispecific, through IND-enabling studies, with TTX-018, an immunology program, less than a year behind. It also appointed Kirsty Crame, M.D., as chief development officer.

Who Is Affected

Sales teams targeting biotech and clinical development services should track T-Therapeutics. The company is shifting from discovery into development, with a new CDO responsible for translational and clinical execution.

Its Optimus platform generates fully human TCRs against previously undruggable targets, and management says TCRs open up around 20 times more targets than antibody-based therapies.

Market Impact

The round validates investor appetite for TCR-based therapeutics, with Big Pharma venture arms from Lilly, J&J, Merck KGaA, and Sanofi participating.

  • TTX-008 is in IND-enabling studies, creating near-term demand for CROs, toxicology, and clinical trial planning.
  • TTX-018 is less than a year behind, extending the development services runway.
  • Prior funding includes a $59M Series A in 2023 and a $32M extension last year.

What to Watch

Watch for IND filing milestones and the start of first-in-human trials for TTX-008. The appointment of Kirsty Crame signals an imminent push into clinical execution.

Also watch whether T-Therapeutics seeks partnerships or additional services as it scales from discovery to clinical-stage operations.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner